STL Index for: Sirolimus

Update on Drugs & Devices: May-June 2022

This update covers Nivolumab + Relatlimab-rmbw for IV use - Opdualag™ (Bristol-Myers Squibb), Sirolimus topical gel 0.2% - Hyftor™ (Nobelpharma America), Oral epinephrine - AQST-109 (Aquestive Therapeutics), and Bimekizumab for SC use - Bimzelx® (UCB Canada Inc.).

Sirolimus: A Therapeutic Advance for Dermatologic Disease

Sirolimus, also known as rapamycin (SRL, Rapamune®), was approved in 1999 by the US Food and Drug Administration to prevent graft rejection in renal transplantation. This articles reviews Sirolimus, its pharmacokinetics, mechanism of action, and indication.

Reducing Skin Malignancy Risk in Organ Transplant Recipients

Skin cancer in organ transplant recipients is a serious problem that manifests as increased squamous cell carcinoma in long-term patients. Education, surveillance, and management of skin cancers in high risk patients are discussed in this article.

Update on Drugs and Drug News: October 2001

Update on: Valacyclovir HCl Valtrex®Tretinoin Gel Retin-A® Micro® Microsphere Drospirenone/Ethinyl Estradiol Yasmin®Agalsidase Beta Fabrazyme™

POPULAR